[go: up one dir, main page]

WO2000060360A3 - Diagnosis of irritable bowel syndrome - Google Patents

Diagnosis of irritable bowel syndrome Download PDF

Info

Publication number
WO2000060360A3
WO2000060360A3 PCT/IE2000/000038 IE0000038W WO0060360A3 WO 2000060360 A3 WO2000060360 A3 WO 2000060360A3 IE 0000038 W IE0000038 W IE 0000038W WO 0060360 A3 WO0060360 A3 WO 0060360A3
Authority
WO
WIPO (PCT)
Prior art keywords
subject
diagnosis
bowel syndrome
irritable bowel
growth hormone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IE2000/000038
Other languages
French (fr)
Other versions
WO2000060360A2 (en
Inventor
Timothy Gerard Dinan
Paul William Napoleon Keeling
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MALOPE Co Ltd
Original Assignee
MALOPE Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MALOPE Co Ltd filed Critical MALOPE Co Ltd
Priority to AU36678/00A priority Critical patent/AU3667800A/en
Publication of WO2000060360A2 publication Critical patent/WO2000060360A2/en
Publication of WO2000060360A3 publication Critical patent/WO2000060360A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/61—Growth hormones [GH] (Somatotropin)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

An in vitro method for the diagnosis of irritable bowel syndrome (IBS) in a subject suspected of having IBS comprises identifying in said subject a dysfunction of central cholinergic receptors, characterised by the subject's growth hormone response to a cholinergic challenge drug more especially an acetylcholinesterase inhibitor such as pyridostigmine or galanthamine. The response is measured by estimating the level of growth hormone in a sample of blood or a blood fraction obtained from said subject following said challenge. When the subject is a premenopausal female, the diagnosis is carried out during the follicular phase of the menstrual cycle.
PCT/IE2000/000038 1999-04-07 2000-04-06 Diagnosis of irritable bowel syndrome Ceased WO2000060360A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU36678/00A AU3667800A (en) 1999-04-07 2000-04-06 Diagnosis of irritable bowel syndrome based on demonstrated central cholinergic supersensitivity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IE990286 1999-04-07
IE990286A IE990286A1 (en) 1999-04-07 1999-04-07 Diagnosis of irritable bowel syndrome based on demonstrated central cholinergic supersensitivity.

Publications (2)

Publication Number Publication Date
WO2000060360A2 WO2000060360A2 (en) 2000-10-12
WO2000060360A3 true WO2000060360A3 (en) 2001-01-04

Family

ID=11042038

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IE2000/000038 Ceased WO2000060360A2 (en) 1999-04-07 2000-04-06 Diagnosis of irritable bowel syndrome

Country Status (3)

Country Link
AU (1) AU3667800A (en)
IE (1) IE990286A1 (en)
WO (1) WO2000060360A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002062345A1 (en) * 2001-02-05 2002-08-15 Janssen Pharmaceutica N.V. Use of galantamine for accelerating transport of intraluminal content

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997008146A1 (en) * 1995-08-31 1997-03-06 The State Of Israel Pyridinium derivatives and pharmaceutical compositions containing them
WO1998030243A1 (en) * 1997-01-08 1998-07-16 Warner-Lambert Company Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997008146A1 (en) * 1995-08-31 1997-03-06 The State Of Israel Pyridinium derivatives and pharmaceutical compositions containing them
WO1998030243A1 (en) * 1997-01-08 1998-07-16 Warner-Lambert Company Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHUA A; KEELING P W N; O'KANE V; DINAN T: "CENTRAL CHOLINERGIC ABNORMALITIES IN PATIENTS WITH THE IRRITABLE BOWEL SYNDROME", GASTROENTEROLOGY, vol. 102, 1992, pages A726, XP000938352 *
COLE S J; WATSON L; KIMBER J R; SILK D B A; MATHIAS C J: "Abnormal central sympathetic function in irritable bowel syndrome detected with the clonidine-growth hormone stimulation test", GASTROENTEROLOGY (DIGESTIVE DISEASES WEEK AND THE 99TH ANNUAL MEETING OF THE AMERICAN GASTROENTEROLOGICAL ASSOCIATION; NEW ORLEANS, LOUISIANA, USA; MAY 16-22, 1998), vol. 114, 15 April 1998 (1998-04-15), pages A736, XP000949286 *
COLE S J; WATSON L; KIMBER J R; SILK D B A; MATHIAS C J: "Abnormal central sympathetic function in irritable bowel syndrome detected with the clonidine-growth hormone stimulation test", GUT (MEETING OF THE BRITISH SOCIETY OF GASTROENTEROLOGY; HARROGATE, ENGLAND, UK; MARCH 10-13, 1998), vol. 42, March 1998 (1998-03-01), pages A95, XP000949326 *
DINAN T G ET AL: "Assessment of central noradrenergic functioning in irritable bowel syndrome using a neuroendocrine challenge test.", JOURNAL OF PSYCHOSOMATIC RESEARCH, (1990) 34 (5) 575-80., XP000938343 *
GHIGO E; BELLONE J; AIMARETTI G; BELLONE S; LOCHE S; CAPPA M; BARTOLOTTA E; DAMMACCO F; CAMANNI F: "Reliability of provocative tests to assess growth hormone secretory status: Study in 472 normally growing children", JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, vol. 81, 1996, pages 3323 - 3327, XP000938349 *
O'KEANE V; DINAN T G: "SEX STEROID PRIMING EFFECTS ON GROWTH HORMONE RESPONSE TO PYRIDOSTIGMINE THROUGHOUT THE MENSTRUAL CYCLE", JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, vol. 75, 1992, pages 11 - 14, XP000938342 *

Also Published As

Publication number Publication date
IE990286A1 (en) 2000-11-01
AU3667800A (en) 2000-10-23
WO2000060360A2 (en) 2000-10-12

Similar Documents

Publication Publication Date Title
KR960029323A (en) Estrogenic agonists / antagonists
WO2001082793A3 (en) Method and device for testing a sample of fresh whole blood
EE200200183A (en) Method for the preparation of Mannich adducts containing polyisobutenephenol
FR2769313B1 (en) DERIVATIVES OF HYDROXYACETIC ESTERS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS SYNTHESIS INTERMEDIATES
WO2001094345A3 (en) Derivatives of 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
EP1118323A3 (en) Method of reducing morbidity and the risk of mortality
MX9705415A (en) Tricyclic benzazepine vasopressin antagonists.
WO2003048333A3 (en) Endorepellin compositions and methods for inhibiting angiogenesis
PT1200103E (en) Xenon as nmda antagonist for neuroprotection
WO2002007718A8 (en) Method for the treatment of climacteric disorders in women during or after the menopause
WO1999006397A3 (en) Pyrrolidine-3-carboxylic acid derivatives and their use as endothelin antagonists
WO2000060360A3 (en) Diagnosis of irritable bowel syndrome
IL160254A (en) Mullerian inhibiting substance levels and ovarian response
Brewer et al. Sporidesmins. Part 16. The structure of chetomin, a toxic metabolite of Chaetomium cochliodes, by nitrogen-15 and carbon-13 nuclear magnetic resonance spectroscopy
ID26346A (en) PROCESS OF MAKING 5-HYDROXYBENZO ACID (b) TIOFEN-3-CARBOXICATE
EP0354180A3 (en) Certain imidazo[4,5-b]pyridine derivatives
HRP20041075B1 (en) PROCEDURE FOR PREPARATION OF OLANZAPINE AND ITS INTERMEDIATE
AU2003267551A1 (en) Thieno-pyrrole compounds as antagonists of gonadotropin releasing hormone
EP2264464A3 (en) Immunoassays for buprenorphine and norbuprenorphine
AU6288700A (en) Novel benzo[f]naphthyridine, preparation and compositions containing them
AR016070A1 (en) CRYSTALLINE POLYMORPHIC FORM 1 OF THE METHYL-METHYL-N3- [2- {3-4- (FORMAMIDINOPHENYL) -ISOXAZOLIN-5 (R) -IL} -ACETIL] -N2- (N-BUTILOXICARBONIL) -2,3- (S) -DIAMINOPROPIONATE (ROXIFIBAN), PHARMACEUTICAL COMPOSITION CONTAINING IT AND ITS USE TO PREPARE A MEDICINAL PRODUCT INHIBITING THE UNION OF A PROTEIN
EP1340821A3 (en) Method of detecting a variant of gh1 as indicator of growth hormone dysfunction
BG103986A (en) Derivatives of pyrrolidinecarboxylic acids as endotheline antagonists
EP1157984A3 (en) Trypsin substrate and diagnostic device, and method of using same
HK1044761A1 (en) Process for the preparation of cefpodoxime acid

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642